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a  b  s  t  r  a  c  t
Some  past  epidemics  of  different  inﬂuenza  subtypes  (particularly  A/H3N2)  in the  US  saw  co-circulation  of
vaccine-type  and variant  strains.  There  is  evidence  that  natural  infection  with  one  inﬂuenza  subtype  offers
short-term  protection  against  infection  with another  inﬂuenza  subtype  (henceforth,  cross-immunity).
This  suggests  that such  cross-immunity  for  strains  within  a subtype  is  expected  to be strong.  Therefore,
while  vaccination  effective  against  one  strain  may  reduce  transmission  of  that  strain,  this  may  also  lead
to a reduction  of the  vaccine-type  strain’s  ability  to  suppress  spread  of a variant  strain.  It remains  unclear
what  the  joint  effect  of vaccination  and  cross-immunity  is for co-circulating  inﬂuenza  strains  within  a
subtype,  and  what  is the  potential  beneﬁt  of  a bivalent  vaccine  that protects  against  both  strains.
We simulated  co-circulation  of vaccine-type  and  variant  strains  under  a variety  of scenarios.  In  each
scenario,  we considered  the  case  when  the vaccine  efﬁcacy  against  the  variant  strain  is  lower  than  the
efﬁcacy  against  the  vaccine-type  strain  (monovalent  vaccine),  as  well  the  case  when  vaccine  is  equally
efﬁcacious  against  both  strains  (bivalent  vaccine).
Administration  of  a bivalent  vaccine  results  in  a signiﬁcant  reduction  in  the  overall  incidence  of  infec-
tion  compared  to administration  of a monovalent  vaccine,  even  with  lower  coverage  by  the  bivalent
vaccine.  Additionally,  we  found  that with greater  cross-immunity,  increasing  coverage  levels  for  the
monovalent  vaccine  becomes  less  beneﬁcial,  while  introducing  the bivalent  vaccine  becomes  more  ben-
eﬁcial.
Our work  exhibits  the  limitations  of inﬂuenza  vaccines  that  have  low  efﬁcacy  against  non-vaccine
strains,  and demonstrates  the beneﬁts  of  vaccines  that  offer  good  protection  against  multiple  inﬂuenza
strains.  The  results  elucidate  the  need  for  guarding  against  the  potential  co-circulation  of  non-vaccine
strains  for  an  inﬂuenza  subtype,  at least  during  select  seasons,  possibly  through  inclusion  of  multiple
strains  within  a subtype  (particularly  A/H3N2)  in a vaccine.
©  2017  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The recurrence of seasonal inﬂuenza epidemics is driven by a
number of factors including waning of immunity, weather-related
changes in transmissibility of inﬂuenza (Shaman et al., 2010), and
antigenic changes in the inﬂuenza virus (Smith et al., 2004). Anti-
genic change creates a need for an update of inﬂuenza vaccines
for each hemisphere every year to every several years (Ampofo
∗ Corresponding author. Present address: Department of Ecology & Evolutionary
Biology, Princeton University, Princeton, NJ 08544, USA.
E-mail address: cworby@princeton.edu (C.J. Worby).
et al., 2015). Despite those updates, there is signiﬁcant circula-
tion in some years of inﬂuenza strains for which the vaccine offers
little protection. The most recent instance of such circulation in
the US and elsewhere took place during the 2014–15 inﬂuenza
season. During that season, vaccine-type A/H3N2 viruses (that is,
A/Texas/50/2012-like viruses) were a majority of A/H3N2 isolated
in the US early in the season (up to week 47) (US CDC, 2014–2015a);
the vaccine-type strain had declined to about 30% of A/H3N2
specimens collected by week 50 (US CDC, 2014–2015b), with the
remainder either showing reduced titers to vaccine-derived antis-
era or belonging to a genetic lineage showing such reduced titers.
The decline in the proportion vaccine-type among A/H3N2 con-
tinued through the rest of the season (US CDC, 2014–2015c). This
http://dx.doi.org/10.1016/j.epidem.2017.02.008
1755-4365/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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predominance of the novel A/H3N2 strain also contributed to the
very low vaccine effectiveness (as measured by the reduction in
the risk of clinical disease) against inﬂuenza A/H3N2 during the
2014–2015 season (US CDC, 2005–2015). The overall effectiveness
of vaccination against inﬂuenza A/H3N2 during 2014–5 in the US
was unusually low at 13%; this overall low effectiveness was a
combination of 43% effectiveness against vaccine-like virus and 9%
effectiveness against “vaccine-low” viruses (US Inﬂuenza Vaccine
Effectiveness Network, 2014–2015).
Competition between co-circulating strains within an inﬂuenza
subtype was observed during previous seasons as well, with a
variety of outcomes. During the 2004–05 season, vaccine-type
viruses initially dominated the 2004–05 A/H3N2 incidence (US
CDC, 2005a), but they were subsequently replaced by a non-vaccine
strain (US CDC, 2005b). Vaccine effectiveness during that season
was very low (US CDC, 2005–2015). When the Fujian A/H3N2 strain
appeared in the US during the 2003–2004 season, that strain had
dominated the circulation of inﬂuenza, and the proportion of the
vaccine strain declined during the course of that season (compare
US CDC, 2003 to US CDC, 2004a to US CDC, 2004b), though the
decline in the proportion of the vaccine-type strain among the
A/H3N2 specimens (from 25% (US CDC, 2003) to 11.5% (US CDC,
2004b)), was not as drastic as for the 2004–05 season. Moreover,
while vaccine effectiveness during the 2003–04 season was  rela-
tively low, it was somewhat higher than during 2004–05 season (US
CDC, 2004c). During the 2007–2008 A/H3N2 season, an antigenic
variant of the vaccine strain circulated at higher levels compared
to the vaccine-type strain (US CDC, 2008a). However, the relative
share of those two strains varied little through the course of the
season (US CDC, 2008b). During the 2011–2012 inﬂuenza B season,
over half the detected B specimens were not of the vaccine type
(US CDC, 2012a). The proportion of vaccine and non-vaccine-type
viruses did not seem to change through the course of that season
(US CDC, 2012b).
When a non-vaccine strain co-circulates and vaccine effective-
ness against it is low (as in 2004–5 and 2014–5), it is commonly
thought that vaccination reduces the incidence of the vaccine-type
strain and has limited impact on mitigating the incidence of a
non-vaccine strain. An additional effect of vaccination that is often
neglected is a potential increase in the incidence of a non-vaccine
strain through reduction of the incidence of the vaccine-type strain,
cutting down on the mitigating effect of the incidence of vaccine-
type strain on the incidence of the non-vaccine strain through
cross-immunity. This cross-immunity, which translates into the
reduction in the risk of infection with one inﬂuenza strain for a
period of time following an infection with another inﬂuenza strain,
is believed to be conferred by a variety of immunological mech-
anisms, and its consequences are documented in the literature.
Sonoguchi et al. (1985) studied the impact of the same-season
circulation of A/H3N2 and A/H1N1 inﬂuenza in Japanese schools,
concluding that infection with A/H3N2 was negatively associated
with subsequent risk of infection with A/H1N1. Cowling et al.
(2010) have found that those infected with seasonal inﬂuenza A
during the 2008–2009 season in Hong Kong had a lower risk of
laboratory-conﬁrmed pandemic A/H1N1 infection. The results in
Cowling et al. (2010) were further extended to show short-term
cross-protection against infection by unrelated viruses (Cowling
and Nishiura, 2012). Ferguson et al. (2003) and Tria et al. (2005)
concluded that strong, transient, nonspeciﬁc immunity effective
against all inﬂuenza strains was needed in the framework of
their models to produce realistic patterns of sequence diversity in
simulations of inﬂuenza A and B evolution. Epidemiological conse-
quences of cross-immunity between different inﬂuenza subtypes
were demonstrated in Goldstein et al. (2011). That paper has shown
that the magnitude of early population incidence of some inﬂuenza
subtypes is negatively correlated with the cumulative seasonal
incidence of other inﬂuenza subtypes. While we are unaware of
any studies directly addressing cross-immunity within a season
and within a subtype, it is expected to be even stronger than
cross-immunity for different inﬂuenza subtypes, rendering infec-
tion twice in the same season with the same subtype quite unlikely.
Though untested, this hypothesis seems plausible in light of the
strong evidence for cross-immunity between inﬂuenza subtypes.
Given cross-immunity within a subtype, the impact of vac-
cination when there is co-circulation of a non-vaccine strain is
uncertain, and the dependence of that impact on the strength of
cross-immunity is unclear. In this paper, we explore these issues
using simulations of inﬂuenza transmission in an age-stratiﬁed
population under a variety of scenarios for transmission param-
eters and vaccination coverage levels. While some of the choices
we make are motivated by data from recent epidemics in the US,
the aim of this work is not to calibrate transmission models to the
actual epidemic data but rather to establish general principles of the
interaction of vaccination and cross-immunity for co-circulating
inﬂuenza strains. The ultimate goal is the elucidation of the need to
guard against the co-circulation of non-vaccine strains (particularly
for inﬂuenza A/H3N2) for which vaccine efﬁcacy is low, possibly by
employing bivalent vaccines for certain inﬂuenza types/subtypes.
In fact, a precedent for this exists, as continuing co-circulation of
the Victoria (vaccine-type) and the Yamagata inﬂuenza B lineages
led to the introduction of a quadrivalent inﬂuenza vaccine contain-
ing both strains starting with the 2013–2014 season, though no
bivalent A/H3N2 vaccine component has ever been adopted by the
WHO.
2. Materials and methods
2.1. Outline
We simulate inﬂuenza outbreaks using a transmission model in
an age-stratiﬁed population for two  co-circulating strains (which
may  be introduced to the population at different times). This is most
relevant to a scenario when one inﬂuenza subtype dominates the
inﬂuenza season, and those two  strains are deemed to be strains
within that subtype. We  compare the performance of several dif-
ferent policies deﬁned by the vaccine coverage and the valency
of vaccine used – these are the two variables that are under the
control of a policy maker (Table 1). A monovalent vaccine has a
lower efﬁcacy against one of the two  strains than the other, while
a bivalent vaccine has equal efﬁcacy against both strains. The out-
come considered in the policy comparison is cumulative incidence
of infection over the course of a season. The policy comparison is
made across a set of scenarios – each scenario deﬁned by one com-
bination of values for the parameters not under a policy maker’s
control: the degree of cross-immunity conferred by natural infec-
tion with one strain against subsequent infection with another, and
several parameters that affect the transmission dynamics of the two
strains (Table 2). Each policy is compared against a baseline policy
of using the monovalent vaccine with 40% coverage for children,
30% for adults, similar to recent US data. We  examine the scenar-
ios when the monovalent vaccine administration varies (is either
reduced or increased relative to the baseline levels, see Table 1) and
compare them to the baseline. Additionally, we consider the case
when a bivalent vaccine (with equal efﬁcacy against both strains)
is used, the same range of coverage levels as for the monovalent
vaccine (Table 1), again comparing outbreak size with the baseline
coverage of monovalent vaccine. We  report the comparisons sep-
arately for three different values of the cross-immunity parameter
, the degree of cross-protection offered by natural infection.
We deﬁne the following parameters – vaccine coverage levels,
valency of vaccine and cross immunity – to be ‘primary parameters’
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Table  1
Coverage levels considered for both the monovalent and the bivalent vaccines in our simulations.
Coverage scenario Monovalent vaccine coverage Bivalent vaccine coverage
Uniform coverage 100% children/100% adults 100% children/100% adults
50%  increase 60% children/45% adults 60% children/45% adults
25%  increase 50% children/37.5% adults 50% children/37.5% adults
10%  increase 44% children/33% adults 44% children/33% adults
Baseline level 40% children/30% adults (Baseline case) 40% children/30% adults
10%  reduction 36% children/27% adults 36% children/27% adults
25%  reduction 30% children/22.5% adults 30% children/22.5% adults
40%  reduction 24% children/18% adults 24% children/18% adults
Table 2
Parameters in the transmission process.
Parameter Meaning Value/source
 Cross-immunity: reduction in the susceptibility to one strain following
natural infection with another strain
90%; 70%; 50%
V  Vaccine valency “Bivalent”; “Monovalent”
L  Vaccine coverage levels in the 5 age groups 40% children, 30% adults (baseline scenario); (37%, 27%); (30%, 22.7%);
(24%, 18%) (alternative)
ni Population size, age group i. Age groups are (0–4, 5–17, 18–49, 50–64,
65+)
US CDC Wonder
cij Contact rate between age groups i and j Mossong et al. (2008)
sk
i
Susceptibility to strain k in age group i Drawn uniformly between [0.75,1] for age groups 1–3; 0.65 for age
group 4; 0.4 for age group 5
w()  Serial interval distribution Cauchemez et al. (2009)
 Scaling parameter for transmission (Eq. (1)) See description following Eq. (1)
D Delay (in days) between the introduction of the ﬁrst infected
individuals for strain 2 vs. 1
Drawn uniformly between [−35,35]
E  Vaccine efﬁcacies against the two  strains for the monovalent and the
bivalent vaccines
Vaccine-type strain: 40%/non-elderly, 30%/elderly. Non-vaccine strain:
40%/non-elderly, 30%/elderly (bivalent vaccine); Drawn uniformly
between [0,20%]/non-elderly, [0,15%]/elderly (monovalent vaccine)
(T1), and all remaining parameters governing transmission
dynamics ‘secondary parameters’ (T2). In order to perform the com-
parisons described in Table 1, we repeatedly draw plausible values
of the secondary parameters, T2, based on estimates form the lit-
erature (Table 2, rows 4–10). For each sampled set of secondary
parameters, we calculate the cumulative incidence of infection
over the course of a season for each of the sixteen vaccine poli-
cies described in Table 1, and for three levels of cross-immunity ,
giving a total of 48 sets of the values of the primary parameters. We
note that with a deterministic model as used here, a choice of the
primary and secondary parameters T1 and T2 completely deﬁnes
an epidemic in the community. For each level of cross immunity,
the outcome under each of ﬁfteen alternative vaccination policies
(described in Table 1) is compared to the outcome with baseline
coverage of monovalent vaccine.
2.2. Transmission model
We  consider two strains, 1 and 2, with 1 being the target of the
monovalent vaccine, which has lower efﬁcacy against 2. We  use
a deterministic, difference equation model with a daily time step,
modeling the spread of these strains in an age- stratiﬁed popula-
tion with 5 age groups (0–4, 5–17, 18–49, 50–64, 65+). Transmission
dynamics are modeled in the stratiﬁed mass action two-strain SIR
(S, I1, I2, R) framework (Dietz, 1979) (with the parameters described
in Tables 2 and 3). Contacts between the different age groups
(strata) are described by a symmetric matrix C = (cij), where cij is
the average number of contacts per unit of time (day) between a
pair of individuals in strata i and j. We  estimate the contact matrix C
by averaging across the country-speciﬁc contact matrices provided
by the POLYMOD study data (Mossong et al., 2008; Wallinga et al.,
2006). Additionally, for each age group i, we have
A. Population size ni (extracted from US CDC Wonder, based on the
2014 US population).
B. Individual relative susceptibility sk
i
≤ 1 (per contact with an
infected individual) for strain k for each individual in stratum
i (uniform susceptibility). We assume that for i ≤ 3, sk
i
is drawn
uniformly between [0.75,1]; sk4 = 0.6, sk5 = 0.45.
Based on previous work (Cauchemez et al., 2009), we assume
that infectivity is age-independent. We  further assume that an
infector causes infections in the community for 7 days following
his/her own  infection, and the distribution w()  of infectiousness
over those 7 days (serial interval distribution) is borrowed from
Cauchemez et al. (2009). Thus, in the absence of vaccination, the
number of infections during the early stage of an epidemic in age
group i caused by a person in age group j on day d (1 ≤ d ≤ 7) after
that person’s own  infection with strain k is
 · w(d) · ski · ni · cij (1)
The leading eigenvalue of the next generation matrix N(i, j) =
 · sk
i
· ni · cij is the initial effective reproductive number for strain
k in the absence of vaccination. We  ﬁx  so when sk
i
= 1 for i ≤ 3
(maximal possible susceptibility), the initial effective reproductive
number (in the absence of vaccination) is 1.4 for both the vac-
cine and the non-vaccine strains. We  discard any parameter sets
for which the initial effective reproductive number is below 1 for
either strain.
Based on data for vaccination levels before the start of seasonal
epidemics in recent years in the US, we assume that in the base-
line case 40% of children and 30% of adults are vaccinated. Little
is known about the efﬁcacy of inﬂuenza vaccine against infection.
The annual estimates published by the US CDC refer to effective-
ness against symptomatic, PCR-conﬁrmed infection episodes–the
latter is expected to be higher than efﬁcacy against inﬂuenza infec-
tion since preventing infection prevents disease. Our previous work
(Worby et al., 2015) suggested that for some pathogens, efﬁcacy of
vaccines against infection can be signiﬁcantly lower than efﬁcacy
against symptomatic disease. We  assume that the inﬂuenza vaccine
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Table  3
Comparative epidemiologic outcomes with the bivalent vaccine coverage from Table 1 compared to the baseline coverage of a monovalent vaccine.
Cross immunity 90% Cross immunity 70% Cross immunity 50%
Coverage for bivalent
vaccine relative to
baseline
% epidemics with
lower cumulative
incidence than
baseline
Average epidemic
size compared to
baseline
(95% CI)
% epidemics with
lower cumulative
incidence than
baseline
Average epidemic
size compared to
baseline
(95% CI)
% epidemics with
lower cumulative
incidence than
baseline
Average epidemic
size compared to
baseline
(95% CI)
Uniform coverage 100% −100%
(−100%, −100%)
100% −100%
(−100%, −100%)
100% −100%
(−100%, −100%)
50%  increase 100% −87%
(−99.9%, −51.6%)
100% −87.10%
(−99.9%, −31.7%)
100% −87.50%
(−99.9%, −60.3%)
25%  increase 100% −63.50%
(−99.7%, −26.6%)
100% −63%
(−99.7%, −31.7%)
100% −62.90%
(−99.7%, −36.7%)
10%  increase 100% −51.40%
(−97.2%, −11.4%)
100% −49.80%
(−97.1%, −15.6%)
100% −48.70%
(−97.1%, −22.1%)
Baseline level 96.60% −43.70%
(−82.4%, 0.1%)
100% −41.30%
(−81.9%, −3.3%)
100% −39.90%
(−80.6%, −9.5%)
10%  reduction 89.70% −36.60%
(−67.4%, 12.2%)
94.40% −33.80%
(−65.7%, 8%)
97% −31.10%
(−63.5%, 2.1%)
25%  reduction 81.60% −26.10%
(−50%, 31.5%)
85.10% −22.50%
(−47.5%, 24.9%)
90% −17.90%
(−43.2%, 18.6%)
40%  reduction 70% −16%
(−35%, 53%)
68.40% −10.80%
(−30.4%, 42.8%)
59.80% −3.30%
(−25.5%, 37%)
reduces susceptibility to a vaccine strain by 40% for non-elderly (age
groups 1–4) and by 30% for the elderly. For the “monovalent” vac-
cine type, we assume that susceptibility to non-vaccine strain is
reduced by x1% for non-elderly, x2% for elderly, where x1 is drawn
uniformly between [0,20] and x2 drawn uniformly between [0,15].
We assume that the start time of the epidemics (introduction of
ﬁrst infected individuals) for the two strains differ by D, where D
is drawn uniformly between [−35,35] days. Once a strain is intro-
duced, it is seeded over a week with 500 cases a day distributed
among the different age groups according to the populations sizes
and susceptibility to that strain. Thus, 3500 cases are seeded in the
population of 318.9 million (estimated US population in 2014).
Once a person is infected with one strain, that person is immune
to it for the rest of the outbreak. Moreover, that person’s suscepti-
bility to the other strain is reduced by %.
Table 2 provides a summary of these concepts. Parameters , V,
L are the primary parameters T1 (with parameters vaccine valency
V and coverage levels L used in the comparisons in Table 1), param-
eters ni, cij, ski , w(), , D, E are secondary parameters T2, as described
in Section 2.1.
3. Results
We  ﬁrst examined the effect of replacing the monovalent
vaccine by a bivalent one under the baseline coverage level. Unsur-
prisingly, the vast majority of simulated outbreaks with a bivalent
vaccine had a smaller cumulative incidence compared to outbreaks
with monovalent vaccine distribution (Fig. 2, panel A1), with a
39.9% average reduction under a cross immunity of 50% (Table 3).
Moreover, the beneﬁt of using a bivalent vaccine compared to
a monovalent one has shown further (modest) increases as the
strength of cross-immunity increased. However, at high levels of
cross immunity (90%), 3.4% of simulated outbreaks were larger
with the implementation of bivalent vaccine relative to monovalent
vaccine (Table 3).
Next, we considered reducing rates of either monovalent
or bivalent vaccination, comparing the cumulative incidence of
infection for the two strains to the scenario of administering a
monovalent vaccine at baseline coverage levels (Fig. 2). Our results
suggest that administration of the bivalent vaccine, even at cov-
erage levels that are 25% lower than the baseline scenario for the
monovalent vaccine, leads on average to a signiﬁcant reduction in
the cumulative incidence compared to the baseline coverage of a
monovalent vaccine. Moreover, under reduced coverage levels, the
beneﬁt of both the bivalent and the monovalent vaccines increase
with increasing strength of cross-immunity (Tables 3 and 4). In rare
cases (about 1% of simulations with high cross-immunity), reduc-
ing coverage for the monovalent vaccine resulted in slightly smaller
outbreaks (Table 4).
We considered increasing vaccination coverage for both the
bivalent and the monovalent vaccines above the baseline coverage
level (Fig. 1). Our results suggest that higher coverage levels for the
bivalent vaccine prevent the majority of incident cases of infec-
tion compared to the baseline coverage of a monovalent vaccine
(Table 3). For example, increasing coverage for the bivalent vaccine
by 50% relative to the baseline completely suppresses transmission
for about 30% of simulated epidemics (Fig. 3); on average, it leads
to an 87% reduction in epidemic size (cumulative incidence) com-
pared to administration of a monovalent vaccine at the baseline
coverage level. At the same time, we found that even increasing
monovalent vaccination to unrealistic levels could not provide the
same level of protection as the bivalent vaccine at the baseline
coverage level. Even universal coverage of the monovalent vaccine
provided a somewhat lower average reduction in cumulative inci-
dence compared to the administration of the bivalent vaccine at
baseline coverage levels (Tables 3 and 4). Additionally, the beneﬁt
of increasing coverage levels for the monovalent vaccine decreases
somewhat with the increasing strength of cross-immunity.
We  noted above certain rare occurrence of some counterintu-
itive results, such as increase in epidemic size when the monovalent
vaccine is replaced by the bivalent one, or decrease in epidemic size
when coverage level for the monovalent vaccine decreases. Those
counterintuitive changes in the cumulative incidence (Fig. 2, points
above the diagonal in panel A1, below the diagonal in panels B2–B4)
are very rare and quite small, with their magnitude being some-
what larger for the decrease in coverage levels for the monovalent
vaccine (panels B2–B4) compared to the introduction of a biva-
lent vaccine (panel A1). Reasons for those counterintuitive results,
as well as the potential explanatory principles behind our main
ﬁndings are presented in the 3rd paragraph of Section 4.
4. Discussion
In this paper we studied the dynamics of co-circulating inﬂuenza
strains and its relation to vaccination. These analyses were moti-
vated by the experience from some of the past inﬂuenza epidemics
in the US when co-circulation of a vaccine-type and non-vaccine
strains within certain inﬂuenza types/subtypes took place (US CDC,
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Table  4
Comparative epidemiologic outcomes with the monovalent vaccine at higher or lower coverage levels compared to the baseline coverage level (Table 1).
Cross immunity 90% Cross immunity 70% Cross immunity 50%
Vaccine coverage
relative to baseline
% epidemics with
lower cumulative
incidence than
baseline
Average epidemic
size compared to
baseline
(95% CI)
% epidemics with
lower cumulative
incidence than
baseline
average epidemic
size compared to
baseline
(95% CI)
% epidemics with
lower cumulative
incidence than
baseline
average epidemic
size compared to
baseline
(95% CI)
Uniform coverage 100% −37.20%
(−99.8%, −0.8%)
100% −38.40%
(−99.8%, −9.1%)
100% −40.30%
(−99.8%, −9.5%)
50%  increase 100% −8.90%
(−47.1%, −1.7%)
100% −10.30%
(−47.7%, 2.5%)
100% −11.80%
(−49.4%, −2.8%)
25%  increase 99.90% −4.40%
(−27.1%, −0.8%)
100% −5.40%
(−26.3%, −1.3%)
100% −6.40%
(−27.8%, −1.4%)
10%  increase 99.10% −1.80%
(−11.9%, −0.3%)
100% −2.20%
(−11.4%, −0.5%)
100% −2.80%
(−11.4%, −0.6%)
10%  reduction 1.30% 1.80%
(0.3%, 12.2%)
0.10% 2.40%
(0.5%, 11.6%)
0% 3.40%
(0.6%, 11.6%)
25%  reduction 1.00% 4.60%
(0.7%, 31.9%)
0% 6.60%
(1.4%, 29.9%)
0% 9.70%
(1.7%, 30%)
40%  reduction 0.90% 7.70%
(1.2%, 52.3%)
0% 11.50%
(2.3%, 49.1%)
0% 17.70%
(2.9%, 49.5%)
2014–2015a,b,c, 2005a,b, 2003, 2004a,b, 2008a,b, 2012a,b). For
some of those seasons, incidence of non-vaccine strains increased
signiﬁcantly relative to the incidence of vaccine-types strains (US
CDC, 2014–2015a,b,c, 2005a,b, 2003, 2004a,b); during other sea-
sons, little relative change in the incidence of the different strains
was observed (US CDC, 2008a,b, 2012a,b). We  examined how
administration of vaccines (that often have higher efﬁcacy against
vaccine-type strains compared to non-vaccine strains), combined
with cross-immunity from natural infections (which is expected to
be high) can affect the relative dynamics of the two  strains. We
also considered the potential beneﬁts of administering vaccines
that impart good protection against both the vaccine-type and the
non-vaccine strains.
We  investigated the impact of the interaction of cross-immunity
and vaccination on the dynamics of co-circulating strains using
numerical simulations in an age-stratiﬁed population. In our sim-
ulations, we considered the baseline scenario of a monovalent
vaccine (which was parameterized to reﬂect the realism of epi-
demics where vaccine was poor for the non-vaccine strain, e.g. the
2004–05 and 2014–15 A/H3N2 epidemics) with vaccination cover-
age levels of 40% for children and 30% for adults. We  matched these
outcomes to epidemics for which vaccine type and coverage lev-
els vary, while all other parameters are the same. This (pair-wise)
comparison of the baseline and matched epidemics demonstrated
that administration of a bivalent vaccine results in a signiﬁcant
reduction in the overall incidence compared to administration of a
monovalent vaccine, often even with reduced coverage levels of the
bivalent vaccine. Moreover, we found that the higher the degree
of cross-immunity, the smaller the reduction in the incidence of
infection that can result from increases in coverage levels for the
monovalent vaccine (Table 4), and the more beneﬁcial the usage
of a bivalent vaccine (Table 3). These results are primarily meant
to suggest the beneﬁt of including multiple A/H3N2 strains in a
vaccine when such strains are expected to circulate.
Our main results are consistent with two simple explanatory
principles. The qualitative ﬁnding in Table 3 is that when two
strains compete for hosts, it is more beneﬁcial to use a bivalent than
a monovalent vaccine. Moreover, this beneﬁt generally increases
with increasing degree of cross-immunity between the different
strains (which is expected to be high, as indicated in Section 1).
We believe that the reason for this is that usage of a monovalent
vaccine reduces the incidence of one strain, decreasing the miti-
gating effect of that incidence on the incidence of the other strain,
with the strength of mitigation being highest for higher degree of
cross-immunity. In certain rare instances, particularly when the
epidemic associated with the vaccine-type strain precedes the one
caused by the non-vaccine strain, and the former epidemic has a
smaller effective reproductive number, vaccination with a mono-
valent vaccine can even result in the increase of the combined
incidence of infection for the two strains, though such increases
in our simulation are very modest (and highly rare). Table 4 shows
that reducing coverage of the monovalent vaccine typically reduces
the population-level beneﬁt of vaccination; however, this reduc-
tion of beneﬁt is less striking when cross-immunity is strong, as
the increase in incidence of the vaccine-type strain is partly offset
by a decline in that of the second strain. We  also note that while all
those rules hold on average, neither of these rules of thumb holds
universally.
This work is meant to illustrate the basic principles under-
lying the interaction of cross-immunity and vaccination under
co-circulation of different strains, rather than make claims about
the actual past inﬂuenza epidemics in the US. During those epi-
demics, even the simpler question of which strain would have
dominated had the vaccine not been administered is not easy
to answer, much less predict in advance. For example, during
the process of vaccine selection for the 2014–15 season, the
A/Switzerland/9715293/2013 A/H3N2 strain was already known
to circulate, but the A/Texas/50/2012 A/H3N2 strain was chosen,
with the non-vaccine strain outstripping the vaccine-type strain
through the course of the season. In Europe, where vaccination
levels are lower than in the US, higher levels of circulation of the
vaccine-type A/H3N2 strain took place compared to the US (ECDC,
2014–2015 vs. US CDC, 2014–2015c). We  note that regardless of the
question which A/H3N2 strain would have been more dominant in
the absence of vaccination during the 2014–15 season, and what
the impact of the administered vaccine was, it is clear that a vac-
cine that contained both the Switzerland/2013 and the Texas/2012
A/H3N2 strains would have been signiﬁcantly more beneﬁcial that
a vaccine that only contained one of those strains.
Our work has several limitations. It is unclear how well the range
of transmission parameters employed here reﬂects the reality of
inﬂuenza epidemics. In our model, vaccine is administered prior
to the beginning of inﬂuenza seasons while in reality, some addi-
tional vaccine administration continues to take place through the
course of inﬂuenza epidemics, at least in the US. The effect of sea-
sonal forcing on the transmission parameters is not modeled in our
study, though this effect should operate independently of the phe-
nomena examined here and presumably has a rather limited impact
on the results. While we  considered three different values for the
strength of cross-immunity parameters, and evidence suggests that
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Fig. 1. Change in cumulative incidence resulting from increased vaccination coverage strategies, relative to baseline coverage of the monovalent vaccine. Each panel represents
a  vaccination scenario; bivalent (left) and monovalent (right) vaccination at increasing coverage levels (top to bottom) are compared to the baseline coverage of monovalent
vaccine. Points denote individual simulations; points below the diagonal represent simulations in which the alternative vaccination strategy reduced the size of the outbreak
relative to the baseline scenario.
this parameter should be fairly large, it is difﬁcult to estimate
using epidemiological or genetic data. Moreover, in our simulations
this parameter was selected independently of the efﬁcacy of the
“monovalent” vaccine against the non-vaccine strain. Given that
signiﬁcant cross-immunity exits between different inﬂuenza sub-
types, this assumption for strains within an inﬂuenza subtype is not
unreasonable, though possibly not entirely accurate. In our simu-
lations, the efﬁcacy of a monovalent vaccine against non-vaccine
strains is assumed to be signiﬁcantly low compared to its efﬁcacy
against the vaccine-type strain. While this was indeed the case
during certain inﬂuenza epidemics, such as the 2014–15 A/H3N2
epidemic in the US (US Inﬂuenza Vaccine Effectiveness Network,
2014–2015), this might not be the case when the non-vaccine
strain belongs to a closely related lineage. Finally, we considered
the impact of vaccination on inﬂuenza incidence during one sea-
son. Incidence of inﬂuenza during a given season has an effect on
80 C.J. Worby et al. / Epidemics 19 (2017) 74–82
Fig. 2. Change in cumulative incidence resulting from reduced vaccination coverage strategies, relative to baseline coverage of the monovalent vaccine. Each panel represents
a  vaccination scenario; bivalent (left) and monovalent (right) vaccination at reducing coverage levels (top to bottom) are compared to the baseline coverage of monovalent
vaccine. Panel B1 represents the baseline case. Points denote individual simulations; points below the diagonal represent simulations in which the alternative vaccination
strategy reduced the size of the outbreak relative to the baseline scenario.
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Fig. 3. (Inverted) cumulative distribution functions (CDFs) for the relative sizes of outbreaks compared to the administration of a monovalent vaccine at the baseline coverage
level.  For each policy (deﬁned by vaccine valency, coverage level, and strength of cross-immunity), a point (X,Y) on the graph suggests that for the proportion X of simulated
epidemics with the lowest relative size (attack rate compared to the administration of a monovalent vaccine at the baseline coverage level), this relative size is at most Y.
incidence during subsequent seasons through long-term immu-
nity, and correspondingly, vaccination has multi-season effects on
incidence as well, even if direct immunity conferred by the vaccine
wanes.
5. Conclusions
Our work provides a framework for understanding several gen-
eral principles related to vaccination (including the administration
of bivalent vaccines) during co-circulation of different inﬂuenza
strains. It illustrates the signiﬁcant limitations that monovalent
vaccines (those that have poor efﬁcacy against non-vaccine strains)
carry and suggests a major improvement in outcomes when biva-
lent vaccines for a given inﬂuenza subtype are administered. We
hope that this work can be used to guide vaccine selection. When
there is evidence (either based on epidemiological data and/or on
the analysis of the evolution of the inﬂuenza virus, e.g. Neher et al.,
2014, 2015) that major circulation on multiple, reasonably distinct
inﬂuenza strains is likely during the upcoming season, our work
stresses the beneﬁt of including multiple strains within an inﬂuenza
subtype, especially inﬂuenza A/H3N2, in a vaccine.
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